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Abstract The leptin system provides a link between adipose
mass and the central nervous system. The appetite suppressing
effects of leptin are impaired in most obese patients and some
mutant mice strains. Herein we describe how suppressor of
cytokine signalling 3 (SOCS3), a potential mediator of this leptin
resistance is recruited into the activated murine leptin receptor
complex. Using a functional assay based on inhibition of leptin
mediated reporter induction, and using phosphopeptide affinity
chromatography we show binding of SOCS3 to the highly
conserved phosphorylated Tyr-985 and Tyr-1077 motifs within
the mouse leptin receptor. ß 2000 Federation of European
Biochemical Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
Leptin, an adipocyte derived hormone, delivers its appetite
suppressing signals by passing the blood-brain barrier and by
binding to the speci¢c signalling form of its receptor in certain
nuclei of the hypothalamus. In this way it constitutes a feed-
back mechanism regulating adipose tissue mass. Mutations
within the leptin system result in a marked obese phenotype
and impaired endocrinological functioning [1,2]. Although the
long signalling form of the leptin receptor shows high expres-
sion levels in these hypothalamic nuclei, it is also expressed in
several peripheral tissues including lung, liver, lymph nodes
and gonads [3,4]. This leads to the involvement of leptin in
several peripheral functions, making it a typical pleiotropic
cytokine.
Until today the therapeutic use of leptin as a weight reduc-
ing agent remains limited [5]. It is observed that in most obese
people a strong correlation exists between adipose mass and
leptin levels, a phenomenon often explained by leptin resis-
tance [6]. A number of possible explanations for this resis-
tance have been suggested: a saturable transport through
the blood-brain barrier resulting in a limited leptin activity
in the hypothalamus [7,8], cross-talk with the glucocorticoid
system [9], or defects at the leptin receptor level, such as
elevated expression of the signalling inhibitor SOCS3 [10].
Being a member of the type 1 cytokine receptor family, the
leptin receptor is activated by cross-phosphorylation of asso-
ciated JAK kinases, most likely JAK2 and/or JAK1 [11,12].
Activation of the leptin receptor leads to recruitment of sig-
nalling molecules containing phosphotyrosine binding SH2
modules. Signal transducers and activators of transcription
(STAT) molecules [13,14] and the receptor associated SH2
containing phosphatase SHP-2 [15,16] are both recruited in
the activated leptin receptor complex. Leptin mediated activa-
tion of mitogen activated protein kinases (MAPK) and insulin
receptor substrate 1 (IRS-1) has been shown in various cell
systems [11,12,17,18].
Leptin can also strongly and rapidly induce the production
of the signal transduction inhibitor suppressor of cytokine
signalling 3 (SOCS3) in various cell types and in vivo
[10,19,20]. SOCS3 is a member of an expanding family of
SH2 containing proteins which are typically built up of a
pre-SH2 domain, a central SH2 domain, and a highly con-
served SOCS box sequence. This last motif is also found in a
number of other signalling molecules [21] and seems to be
connected with proteasome function [22]. The observation
that the leptin resistant Ay/a mutant mice strain shows ele-
vated SOCS3 levels makes this protein a possible mediator of
leptin resistance [10].
Recently it has been shown that a tyrosine recruitment site
within gp130, the signalling component of the IL-6 complex,
is required for binding and thus for the inhibitory activity of
SOCS3 [23,24]. This is in contrast to SOCS1, which binds
directly to JAK kinases and directly inhibits their kinase ac-
tivity [25]. Similar results have been obtained for the insulin
receptor and the erythropoietin receptor [26,27].
In previous studies we have shown that leptin induces two
gene sets in the PC12 rat pheochromocytoma cell line stably
expressing the mouse leptin receptor. Many of these genes
appear to be regulated in vivo [20]. Using a mutational ap-
proach we have also shown that in the mouse leptin receptor
residue Y985 is involved in a negative feedback signal, and
furthermore that this e¡ect is more pronounced when mutated
in concert when another tyrosine, Y1077 [28]. In this report,
we analyze the role of both residues in SOCS3 recruitment.
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2. Materials and methods
2.1. Antibodies, growth factors and peptides
Monoclonal anti-FLAG antibody M2 was obtained from Sigma.
Mouse recombinant leptin was purchased from R and D Systems.
Peptides were synthesized using standard Fmoc amino acid solid
phase chemistry on an Applied Biosystems Model 431A peptide syn-
thesizer. Biotin was esteri¢ed manually following similar procedures
as on the synthesizer, and added to the reaction mixture. Incorpora-
tion of phosphotyrosine was realized by using a protected Fmoc ty-
rosine phosphobenzylester (Novabiochem). After puri¢cation, mass of
the peptides was con¢rmed by mass spectrometry. Sequences of the
peptides used were biotin-QRQPSVK(p)Y985ATLVSNDK and biotin-
NHREKSVC(p)Y1077LGVTSVNR.
2.2. Vectors
The pMET7-LR long isoform was kindly provided by L. Tartaglia.
Generation of the leptin receptor mutants was described elsewhere
[28].
Rat SOCS3 cDNA was ampli¢ed using 5P-GAAGATCTGTGCGC-
CATGGTCACCCACAGCAAGTT and 5P-GCTCTAGATTTTGCT-
CCTTAAAGTGGAGCATCATA as forward and reverse primer re-
spectively, and using mRNA from leptin stimulated PC12 cells as
template. cDNA was prepared using a standard RT procedure with
superscript reverse transcriptase (LifeTechnologies). Ampli¢cation
was realized using Pfu polymerase (Stratagene). The SOCS3 fragment
was reampli¢ed using forward primer 5P-GCGAGATCTCA-
GAATTCGTCACCCACAGCAAGTTTCC and the reverse primer
described above, which allows BglII-XbaI based cloning in a
pMET7 variant containing an N-terminal FLAG tag sequence (MD-
YKDDDDK). The pUT651 construct expressing L-galactosidase was
obtained from Eurogentec. Generation of the pGL3-rPAP1-luci con-
struct was described before [28]. The full-length rPAP1 promoter frag-
ment was excised using partial digestion with KpnI and XhoI and
ligated into the KpnI-XhoI digested pXP2d2 vector (gift from Prof.
S. Nordeen), resulting in the leptin responsive pXP2d2-rPAP1-luci
reporter construct. The pXP2d2 vector is a derivative of pXP2 that
lacks potential cryptic activator protein 1 sites [29]. All constructs
were veri¢ed by restriction and sequence analysis.
2.3. Cell lines and transfection procedures
Culture conditions and transient transfection procedures for PC12
and generation of the PC12LR8 cell line were as previously described
[28,20].
HEK293T cells were maintained in a 10% CO2 humidi¢ed atmos-
phere at 37‡C, and were grown using DMEM with 4500 mg/l glucose,
10% fetal bovine serum and 50 Wg/ml gentamicin (all from LifeTech-
nologies). Typically, 4U105 cells were seeded the day before trans-
fection in a 6-well plate and transfected overnight with approximately
2 Wg plasmid DNA using a standard calcium phosphate precipitation
procedure. One day after transfection, cells were resuspended with cell
dissociation agent (LifeTechnologies), seeded in a black well plate
(Costar), and stimulated overnight with 100 ng/ml leptin, or left un-
stimulated.
2.4. Reporter assays and Northern blot
Luciferase assays, binding assays using leptin-SEAP, and Northern
blot hybridizations with SOCS3 and actin probes were described pre-
viously [28]. L-Galactosidase activity was measured using the Galacto-
Star1 chemiluminescent detection kit (Tropix) and a Topcount
Chemiluminescence Counter (Packard).
2.5. Western blot analysis and phosphopeptide a⁄nity chromatography
Approximately 106 HEK293T cells were lysed in 150 Wl 2U loading
bu¡er. After sonication, 30 Wl was loaded on a 10% polyacrylamide
gel. After overnight blotting, FLAG-tagged SOCS3 was revealed us-
ing a 1/2500 dilution of anti-FLAG antibody. Blotting e⁄ciency was
checked using PonceauS staining (Sigma). For phosphopeptide a⁄nity
chromatography, approximately 3U107 HEK293T cells transiently
transfected as indicated were lysed in lysis bu¡er (20 mM HEPES
pH 7; 1 mM MgCl2 ; 10 mM KCl; 0.5 mM DTT; 150 mM NaCl;
0.5% NP40; 1 mM NaVO4 ; 5 mM NaF; 20% glycerol; Complete1
Protease Inhibitor Cocktail [Roche]). Precipitated material was
cleared by 5 min centrifugation at 10 000Ug. To eliminate a-speci¢c
interactions, supernatants were brought on a precolumn containing
Fig. 1. SOCS3 mediated inhibition of leptin signalling is critically
dependent on the presence of either Y985 or Y1077 in the murine
leptin receptor. A: Schematic representation of the long isoform of
the murine leptin receptor (LRlo), showing extracellular (EC), trans-
membrane (TM) and intracellular (IC) parts. The box1 motif and
the three tyrosines involved in signal transduction are also shown.
B: Hek293T cells were transiently co-transfected with plasmids en-
coding di¡erent leptin receptor variants, SOCS3 or empty vector,
together with the pXP2d2-rPAP1-luci reporter construct. The trans-
fected cells were either stimulated for 24 h with leptin or were left
untreated. Luciferase measurements were performed in triplicate and
were normalized by co-transfection with the pUT651 L-galactosidase
construct and a L-galactosidase activity assay. Results are shown in
fold induction and are representative for three separate transfection
experiments. Signi¢cance for the results obtained for LRlo, Y985F
and Y1077F was P6 0.001 when the three separate experiments
were pooled and analyzed by two-way ANOVA. C: LR expression
levels were measured on transfected cells by incubation for 90 min
with leptin-SEAP fusion protein with or without excess leptin
(100U). Bars show mean values and S.D. values of triplicate mea-
surements. D: Western blot analysis of SOCS3 expression. The
FLAG-tagged SOCS3 protein was revealed in lysates of transfected
cells using anti-FLAG antibody. CPS, absolute luminescence counts
per second; LRlo, leptin receptor long isoform.
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Sepharose 4B beads, prior to phosphopeptide a⁄nity chromatography
on streptavidin coupled agarose beads (Sigma). Peptide concentra-
tions were determined by a colorimetric assay using alkaline hydroly-
sis and a ninhydrin reagent. 50 Wl of streptavidin^agarose slurry was
incubated with 5 nmol of peptide for each reaction. Cleared lysate was
incubated for 2 h at 4‡C under slow stirring. After incubation, beads
were washed four times with lysis bu¡er and resuspended in 2U
loading bu¡er.
3. Results and discussion
The observation that most human obese patients show ele-
vated levels of leptin suggests the existence of a so-called
leptin resistance [6]. SOCS3, a potential mediator of this re-
sistance [10] is a member of a family of SH2 domain contain-
ing proteins mostly involved in negative regulation of signal
transduction pathways [21]. Through representational di¡er-
ence analysis, a PCR based di¡erential expression screening,
we were able to identify several leptin induced transcripts,
including SOCS3, in PC12 cells expressing the mouse leptin
receptor. In order to check the inhibitory role of SOCS3, we
generated an expression vector containing rat SOCS3. Tran-
sient expression of SOCS3 in HEK293T cells together with the
leptin responsive pXP2d2-rPAP1-luci construct leads to
marked inhibition of reporter induction (Fig. 1B: results for
LRlo). The rPAP1 promoter is derived from the rat pancrea-
titis associated protein 1 gene and shows strong induction
upon treatment with leptin ([20] and Broekaert et al., in prep-
aration). Similar ¢ndings were obtained in PC12LR8 cells
[20], a PC12 clone that stably expresses the leptin receptor
(data not shown).
Recently it has been shown that SOCS3 can mediate its
inhibitory activity by binding to activated receptors although
the exact mechanism of inhibition remains unclear. Binding of
SOCS3 was demonstrated for the gp130 signalling component
of the IL-6 complex [23,24], the erythropoietin receptor [27]
and the insulin receptor [26]. Based on the functional similar-
ities between the leptin receptor and the gp130 chain [13], we
tested the leptin receptor for interaction with SOCS3. The
murine leptin receptor contains three tyrosine residues within
its cytoplasmic domain (Fig. 1A). Y1138 is situated within a
box3 or STAT3 recruitment motif and is involved in leptin
mediated gene induction [30]. We previously showed a critical
role in negative feedback for the Y985 and to a lesser extent
also for the Y1077 residue [28]. Leptin receptor variants con-
taining Y to F mutations at positions Y985, Y1077, or at both
sites, were tested in a functional assay based on rPAP1 induc-
tion. Signalling via the leptin receptor variants was analyzed
upon transient transfection in HEK293T cells with the
pXP2d2-rPAP1-luci and the FLAG-tagged pMET7-fSOCS3
expression construct. Luciferase activity data were normalized
by co-transfection with pUT651 and a L-galactosidase activity
assay (Fig. 1B). Expression of leptin receptor variants and
SOCS3 was con¢rmed respectively by a binding assay using
a leptin-SEAP fusion protein (Fig. 1C) and Western blot anal-
ysis using an anti-FLAG antibody (Fig. 1D). The results in-
dicated a strong inhibitory activity of SOCS3 (80^90% inhibi-
tion) when either the wild-type or the mutant Y1077F leptin
receptor was expressed, and a moderate inhibition (30^50%
inhibition) upon expression of a Y985F receptor variant. In
case of the double Y985/1077F mutant no inhibition was ob-
served.
The interaction sites of SOCS3 with the leptin receptor were
con¢rmed using a biochemical approach. FLAG-tagged
SOCS3 was expressed upon transient transfection of
pMET7-fSOCS3 in HEK293T cells, and was analyzed for
binding to (phospho)-tyrosine containing peptides matching
the two motifs within the leptin receptor. Lysates of approx-
imately 3U107 transfected cells were incubated with biotinyl-
ated peptides encompassing residue Y985 or Y1077 in the
leptin receptor. Western blot analysis using an anti-FLAG
antibody showed clear and speci¢c binding of SOCS3 to the
phosphorylated Y985 peptide, while non-phosphorylated pep-
tide did not bind any SOCS3 protein. SOCS3 also binds spe-
ci¢cally to the phosphorylated Y1077 peptide but apparently
with a much lower a⁄nity con¢rming its accessory role in
SOCS3 mediated inhibition (Fig. 2).
To assess the e¡ect of Y to F mutations within the leptin
receptor on SOCS3 expression itself, Northern blot analysis
was performed on lysates from transiently transfected PC12
cells. The neuronal di¡erentiation pattern and the fact that
Fig. 2. SOCS3 binding to peptides matching the murine leptin re-
ceptor Y985 and Y1077 sites is phosphorylation dependent. Lysates
of Hek293T cells overexpressing FLAG-tagged SOCS3 protein were
incubated with peptides matching leptin receptor Y985 and Y1077
sites, either phosphorylated or not. Speci¢c binding of SOCS3 was
revealed by immunoblotting using an anti-FLAG antibody.
Table 1
Conservation of the Y985 and Y1077 motifs within the leptin receptor
The conserved tyrosine is shown boxed; a conserved serine at position +5 (or +6) found in both motifs is shown in bold. Asterisks below indi-
cate conserved amino acid residues shared by both motifs. Dashes in the Y1077 motif were introduced for optimal alignment.
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several of the leptin induced genes in these cells also show in
vivo modulation [20], makes this cell line a valuable model
system to study leptin signalling. 48 h after transfection, cells
were stimulated for 24 h with leptin (100 ng/ml) or were left
untreated (Fig. 3). Previously obtained results indicate that
SOCS3 transcription is rapidly induced in PC12 cells with
an optimum around 30 min, but that weak SOCS3 expression
persists until later time points [20]. Results shown in Fig. 3
imply that during this late induction phase, mutation of Y985
results in a strong up-regulation of SOCS3 transcription. This
occurs only in conjunction with Y1138, a STAT3 activation
site, indicating that SOCS3 expression is STAT dependent, as
has been shown before for signalling via the IL-6 and leuke-
mia inhibitory factor receptors [31]. Absence of the Y1077 site
does not lead to altered SOCS3 mRNA expression, but lack
of both sites results in a further increased induction level
above what is observed for the Y985 mutant alone. These
results are in line with our previous results for metallothionein
II mRNA regulation and rPAP1 induction [28]. A possible
explanation for the elevated SOCS3 expression level could
be the loss of negative feedback via either SOCS3 itself, or
alternatively via the SH2 containing phosphatase SHP-2
[15,16].
Taken together, these ¢ndings suggest that both tyrosines
are involved in SOCS3 recruitment to the activated leptin
receptor complex although binding to the Y1077 position ap-
parently occurs at signi¢cantly lower e⁄ciency suggesting an
accessory role for this site. This observation could explain
why, at late time points post stimulation, the single Y1077
mutant does not lead to detectable di¡erences on induction
of metallothionein II and SOCS3 genes when compared to the
wild-type receptor, whereas a more pronounced induction is
observed when the double Y985/1077F mutant is compared to
the Y985F receptor variant (see Fig. 3, and also [28]). In line
with these ¢ndings, recruitment of SOCS3 at the single phos-
phorylated Y1077 motif shows a moderate inhibition of leptin
signalling (Fig. 1). Perhaps this accessory role of the Y1077
motif is only functional when expression levels of SOCS3 are
highly elevated, suggesting di¡erent threshold levels for leptin
receptor signalling may exist. Although several groups were
not able to show leptin dependent phosphorylation of the
Y1077 site in the leptin receptor using anti-phosphotyrosine
antibodies [12,16], our results indicate a functional phosphor-
ylation dependent role for this site in leptin signalling. This
could perhaps be explained by the fact that the anti-phospho-
tyrosine antibodies used do not recognize this site, or that
only marginal phosphorylation occurs. This latter possibility
could be mediated by the presence of a signalling protein that
binds (close to) the Y1077 site, preventing its recognition by
kinases.
Functionality of the Y1077 motif is also strongly suggested
by the cross-species conservation of this sequence. In fact,
Y1077 is part of a highly conserved motif extending 10 amino
acids downstream of the tyrosine residue (Table 1). This motif
is also related to the Y985 £anking sequence, with conserved
hydrophobic residues at positions 32, +1 and +3, and a con-
served basic residue at +8. Intriguingly, besides this conserved
motif encompassing a canonical SHP-2 binding site [32], a
serine residue also appears to be conserved within both motifs
at position Y+5, suggesting a shared function. This serine is
shifted to position +6 in the horse and ovine LR Y985 motif
due to an extra glycine at position +5. Perhaps, phosphory-
lation at this serine residue may modulate the interaction with
signalling regulators. Taken together, the pattern of conserva-
tion of the Y985 and Y1077 motifs provides a molecular basis
for the binding of both shared, such as SOCS3, and unique
signalling components. The very pronounced conservation of
the Y1077 motif also underscores its functional importance in
leptin signalling.
It has been demonstrated that the SH2 containing phospha-
tase SHP-2 is also recruited to the phosphorylated Y985 motif
receptor [15,16]. It therefore appears that at least two signal
modulating proteins can bind to the phosphorylated Y985
site, suggesting a complex control of leptin receptor (in)acti-
vation. Insights in the relative binding a⁄nities and spatio-
temporal expression patterns of these signalling modulators
may help understand leptin resistance.
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